IMI2 - Call 17
Call ID: H2020-JTI-IMI2-2019-17-two-stage
Action Type: RIA – Research and Innovation Actions
- Topic 1: Optimising future obesity treatment
- Topic 2: Open access chemogenomics library and chemical probes for the druggable genome
- Topic 3: Intelligent prediction and identification of environmental risks posed by human medicinal products
For full details of the topics, including the budget breakdown and the General Conditions for the Call for proposals, click on the links above (which take you directly to the relevant page of the Funding & Tenders Portal) or read the IMI2 - Call 17 Text.
- From EFPIA companies and IMI2 Associated Partners: EUR 43 108 139
- From the IMI2 JU: EUR 40 786 000
Key dates and deadlines
- Draft topic texts published: 15 October 2018
- Call launch date: 22 January 2019
- Stage 1 submission start date: 22 January 2019
- Stage 1 submission deadline: 25 April 2019 (17:00:00 Brussels time)
- Stage 2 submission deadline: 07 November 2019 (17:00:00 Brussels time)
How to apply
All documents relating to the Call can be found via the Funding & Tenders Portal and the IMI2 Call documents page, in particular the IMI Manual for evaluation, submission and grant award - version 1.7.
Proposals must be submitted via the electronic submission system of the Horizon 2020 Funding & Tenders Portal. To start submitting your proposal, simply click on the relevant topic above - this will take you directly to that topic's page. Once there, scroll down and click on 'Start submission'.
- Catch up on the IMI2 – Call 17 webinars.
- Read our tips for applicants and advice on finding project partners.
An organisation from a third country may participate as a partner in a proposal (article 7 of Regulation 1290/2013, H2020 Rules of Participation).
Under IMI2 JU, only organisations from EU and H2020 associated countries are in principle eligible for IMI funding. Additionally, for that these organisations to be actually funded, they have to fulfil the conditions for funding in the IMI 2 JU context (Article 1 of Regulation 622/2014).
However, legal entities established in third countries (Non EU nor H2020 Associated countries, e.g. Russia) may – exceptionally - be eligible for funding if their participation is deemed to be essential by the IMI2 JU for carrying out the action. Please note that this is exceptional and it has to be assessed during the evaluation phase considering the objectives of the action (based on adequate justification).
- ‘Essentiality’ with regards to an entity’s necessary inclusion in an IMI2 JU project is made on the scientific merits of the contribution made to the project and as such is assessed by the IMI2 evaluation panel, i.e. independent experts.
- This necessity should be of such a character that the given IMI2 JU project would be unable to achieve its objectives without the inclusion of that entity, e.g. a similar expertise is not available within the EU or H2020 associated countries.
As a general guideline, the participation is deemed essential for carrying out the action by the IMI2 JU on the grounds that participation by the applicant has clear benefits for the consortium, such as:
- outstanding competence/expertise;
- access to research infrastructure;
- access to particular geographical environments;
- access to data.
As in the case of organisations from EU and H2020 associated countries, the ‘essential’ legal entity from a third country should also fulfil the conditions for funding of Article 1 of the Commission Delegated Regulation No 622/2014.
The use of this template is mandatory for all clinical studies in all stage 2 proposals. This has to be uploaded as a separate part of the application in the submission system.